Pérez-Calatayud ÁA

Idioma: Español
Referencias bibliográficas: 36
Paginas: 387-392
Archivo PDF: 197.27 Kb.

RESUMEN

La hemorragia masiva puede ser un padecimiento que pone en peligro la vida, ésta se observa con mayor frecuencia en escenarios de trauma o cirugía. Los enfermos que reciben terapia anticoagulante presentan un riesgo de sangrado mayor. El motivo de esta revisión es resaltar la evidencia actual del uso del concentrado de complejo protrombínico en diferentes escenarios.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ageno W, Gallus AS, Wittkowsky A, Growther M, Hylek EM, Palareti G. Oral anticoagulant therapy, antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S-e88S.

2. Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thrombosis Res. 1999;95:S7-S12.

3. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost. 2012;10:1841-1848.

4. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.

5. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87:S141-S145.

6. Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban. J Thromb Haemost. 2013;11:1111-1118.

7. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost. 2012;10:1830-1840.

8. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomized crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217-224.

9. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98:790-797.

10. Behring CSL. KcentraTM prescribing information. 2013 [accessed 23 December 2013]. Available in: http://www.kcentra.com/prescribing-information.aspx

11. Hanke AA, Joch C, Gorlinger K. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. Br J Anaesth. 2013;110:764-772.

12. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced over anticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;115:998-100.

13. Yasaka M, Sakata T, Minematsu K, Maritomi H. Correction of INR by prothrombin comoplex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res. 2003;108:25-30.

14. Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B, et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med. 1999;25:1105-1110.

15. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care. 2011;15:201.

16. Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95:S13-S17.

17. Köhler M, Hellstern P, Lechler E, Uberfuhr P, Müller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost. 1998;80:399-402.

18. Key NS, Negreir C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370:439-448.

19. Kinard TN, Sarode R. Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal. Expert Rev Cardiovasc Ther. 2014;12:417-427.

20. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. Chest. 2012;141:152s-184s.

21. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin-fourth edition. Br J Haematol. 2011;154:311-324.

22. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116:619-624.

23. Sarode R, Milling TJ Jr., Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of four-factor prothrombin complex concentrate (4F-PCC) in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma controlled, phase IIIb study. Circulation. 2013;128:1234-1243.

24. Refaai MA, Goldstein JN, Milling TJ Jr., Lewis B, Goldberg-Alberts R, Hug BA, et al. Randomized phase IIIb study of rapid vitamin K antagonist reversal In patients requiring an urgent surgical procedure: four-factor prothrombin complex concentrate is superior to plasma. Proceedings of the 55th American Society of Hematology. New Orleans, LA, USA, 3588 (2013). Annual Meeting Abstracts Blood. 2013;122:423.

25. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J thromb Haemost. 2008;6:622-631.

26. Mitterlechner T, Innerhofer P, Streif W, Lödl M, Danninger T, Klima G, et al. Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant F X and FVIIa in dilutional coagulopathy: a porcine model. JThromb Haemost. 2011;9:729-737.

27. Grottke O, Braunschweig T, Spronk H, Esch S, Rieg A, van Oerle R, et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood. 2011;118:1943-1951.

28. Griffe MJ, DeLoughery TG, Thorborg PA. Coagulation management in massive bleeding. Curr Opin Anesthesiol. 2010;23:263-268.

29. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol. 2007;73:401-415.

30. Bruce D, Nokes TJC. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12:R105.

31. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, et al. Management of bleeding following major trauma: an updated European guideline. Critical Care. 2010;14:R52.

32. Cushing M, Shaz BH. Blood transfusion in trauma patients: unresolved questions. Minerva Anestesiol. 2011;77:349-359.

33. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res. 2001;101:145-157.

34. Heindl B, Spannagl M. New oral anticoagulants. Consecuences for perioperative coagulaction diagnostics and therapy. Anesthesist. 2009;58:1252-1255.

35. Levy JH, Azran M. Anesthetic concerns for patients with coagulopathy. Curr Opin Anesthesiol. 2010;23:400-405.

36. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Hemost. 2010;103:572-585.